Your browser doesn't support javascript.
loading
End of life decisions in immunocompromised patients with acute respiratory failure.
Burghi, Gaston; Metaxa, Victoria; Pickkers, Peter; Soares, Marcio; Rello, Jordi; Bauer, Philippe R; van de Louw, Andry; Taccone, Fabio Silvio; Loeches, Ignacio Martin; Schellongowski, Peter; Rusinova, Katerina; Antonelli, Massimo; Kouatchet, Achille; Barratt-Due, Andreas; Valkonen, Miia; Pène, Frédéric; Mokart, Djamel; Jaber, Samir; Azoulay, Elie; De Jong, Audrey.
  • Burghi G; Terapia Intensiva, Hospital Maciel - Montevideo, Uruguay.
  • Metaxa V; College Hospital, London SE5 9RS, UK.
  • Pickkers P; The Department of Intensive Care Medicine (710), Radboud University Medical Centre, Nijmegen, the Netherlands.
  • Soares M; Terapia Intensiva, Hospital Maciel - Montevideo, Uruguay.
  • Rello J; CIBERES, Universitat Autonòma de Barcelona, European Study Group of Infections in Critically Ill Patients (ESGCIP), Barcelona, Spain.
  • Bauer PR; Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
  • van de Louw A; Penn State University College of Medicine, Division of Pulmonary and Critical Care, Hershey, PA, USA.
  • Taccone FS; Department of Intensive Care, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Loeches IM; Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, Dublin, Ireland.
  • Schellongowski P; Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Rusinova K; Department of Anesthesiology and Intensive Care Medicine and Institute for Medical Humanities, 1st Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.
  • Antonelli M; Agostino Gemelli University Hospital, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Kouatchet A; Department of Medical Intensive Care Medicine, University Hospital of Angers, France.
  • Barratt-Due A; Department of Emergencies and Critical Care, Oslo University Hospital, Oslo, Norway.
  • Valkonen M; Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki 00014, Finland.
  • Pène F; Medical ICU, Cochin Hospital, Assistance Publique-Hôpitaux de Paris and University Paris Descartes, Paris, France.
  • Mokart D; Réanimation Polyvalente et Département d'Anesthésie et de Réanimation, Institut Paoli-Calmettes, Marseille, France.
  • Jaber S; Department of Anesthesia and Intensive Care unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Phymedexp, Université de Montpellier, Inserm, CNRS, CHRU de Montpellier, Montpellier, France.
  • Azoulay E; Medical Intensive Care Unit, Hôpital Saint-Louis and Paris Diderot Sorbonne University, 1 avenue Claude Vellefaux, cedex 10 75475, Paris.
  • De Jong A; Department of Anesthesia and Intensive Care unit, Regional University Hospital of Montpellier, St-Eloi Hospital, University of Montpellier, Phymedexp, Université de Montpellier, Inserm, CNRS, CHRU de Montpellier, Montpellier, France. Electronic address: a-de_jong@chu-montpellier.fr.
J Crit Care ; 72: 154152, 2022 12.
Article en En | MEDLINE | ID: mdl-36137351
ABSTRACT

PURPOSE:

To identify patient, disease and organizational factors associated with decisions to forgo life-sustaining therapies (DFLSTs) in critically ill immunocompromised patients admitted to the intensive care unit (ICU) for acute respiratory failure. MATERIAL AND

METHODS:

We performed a secondary analysis of the international EFRAIM prospective study, which enrolled 1611 immunocompromised patients with acute respiratory failure admitted to 68 ICUs in 16 countries between October 2015 and June 2016. Multivariate logistic analysis was performed to identify independent predictors of DFLSTs.

RESULTS:

The main causes of immunosuppression were hematological malignancies (50%) and solid tumor (38%). Patients had a median age of 63 yo (54-71). A pulmonologist was involved in the patient management in 38% of cases. DFLSTs had been implemented in 28% of the patients. The following variables were independently associated with DFLSTs 1) patient-related older age (OR 1.02 per one year increase, 95% confidence interval(CI) 1.01-1.03,P < 0.001), poor performance status (OR 2.79, 95% CI 1.98-3.93, P < 0.001); 2) disease-related shock (OR 2.00, 95% CI 1.45-2.75, P < 0.001), liver failure (OR 1.59, 95% CI 1.14-2.21, P = 0.006), invasive mechanical ventilation (OR 1.79, 95% CI 1.31-2.46, P < 0.001); 3) organizational having a pulmonologist involved in patient management (OR 1.85, 95% CI 1.36-2.52, P < 0.001), and the presence of a critical care outreach services (OR 1.63, 95% CI 1.11-2.38, P = 0.012).

CONCLUSIONS:

A DFLST is made in one in four immunocompromised patient admitted to the ICU for acute respiratory failure. Involving a pulmonologist in patient's management is associated with less non beneficial care.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de Dificultad Respiratoria / Insuficiencia Respiratoria Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de Dificultad Respiratoria / Insuficiencia Respiratoria Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article